Can-C™ contains a unique form of N-acetylcarnosine which has been shown in animal and clinical trials to help reduce, slow and even reverse the occurrence of senile cataract.
Senile cataract is the most commonly performed surgical operation in the world today. Some 26,000 people each year, in the United States alone, are diagnosed with senile cataract each day. There are 1.35 million eye operations each year in the USA and 2% of them (27,000 individuals) develop serious complications as a direct result of their cataract surgery.
Apart from the discomfort experienced by patients as their vision diminishes, and the possibility of being one of the surgical complications, it should not be overlooked that there is a complete lack of accommodation by the removal of the lens. It is obvious that an artificial lens does not have the optical quality of a natural lens.
Can-C eye-drops are therefore a major advancement in the control of the age-related disorder of senile cataract.
The statistics in the human trials show that Can-C eye-drops applied for 6-months (twice daily into the eye), in patients all suffering from senile cataract, had the following results:
This is a genuine breakthrough, because before the development of Can-C eye-drops, the best that could be hoped for would be a slowing of the disorder. So now for the very first time, it has been shown that senile cataract can be influenced without surgery.
In addition to senile cataract, Can-C may also have other benefits. Although the information is not yet published, scientists believe that the unique Can-C formula with its added and synergistic lubricants, could also have benefit in the following eye disorders.